Phase 1b dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.
Publication Title
Haematologica
Document Type
Article
Publication Date
12-23-2021
Keywords
seattle; swedish cancer; washington
Abstract
Not available.
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
COinS
